Understanding Prostate Cancer
Clinical drug trials play a crucial role in moving new treatments to patients who need them most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients.
There are currently more than several Phase III drug trials and more than 90 Phase I/II trials in process for prostate cancer in North America and Europe. Those that are approved will join the five new drugs that have been approved for men with advanced metastatic disease in the past two years and further improve outcomes for patients:
Xofigo (radium 223 dichloride)
The resources on this page can direct you to clinical trials that are currently open for enrollment in your local area, as well as across the country. If you are considering a clinical trial, speak to your doctor about the potential benefits of participating in a trial so you can make an informed decision that is best for you.
Frequently Asked Questions (FAQs)
To view our FAQs about Clinical Trials, please visit here.
The Prostate Cancer Clinical Trials Consortium (PCCTC) is a 13-member clinical research group sponsored by the Prostate Cancer Foundation and the Department of Defense Prostate Cancer Research Program (PCRP), with its Coordinating Center headquartered at Memorial Sloan-Kettering Cancer Center.
Visit the PCCTC site for trial information: www.pcctc.org
The SPARTAN Study
A clinical research study for patients whose prostate cancer has not spread beyond the prostate is now enrolling
Aragon Pharmaceuticals is seeking men to participate in a clinical trial of an investigational drug for prostate cancer. The purpose of the SPARTAN study is to evaluate the safety and effectiveness of an investigational drug in delaying prostate cancer from spreading beyond the prostate. This study is enrolling patients with prostate cancer who, despite treatment, have rising blood prostate-specific antigen (PSA) levels. All participants will continue to receive their current treatment along with either the investigational medication or a placebo. The selections will be random, and the investigational medication will be given to 2 out of every 3 study participants.
Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson and provides various services to its affiliate, Aragon Pharmaceuticals, Inc.
A clinical research study for patients with asymptomatic/mildly symptomatic castration resistant prostate cancer and two or more bone metastases Bayer HealthCare is seeking men to participate in a research study of radium-223. The purpose of the ERA 223 trial is to determine if the addition of radium-223 to abiraterone acetate is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as bone fractures or bone pain which needs to be treated with an X-ray machine. This study is enrolling patients with prostate cancer who, despite medical or surgical castration, have rising blood prostate-specific antigen (PSA) levels. Eligible patients must have two or more bone metastases with no visceral, e.g. liver, metastases and must not have received prior chemotherapy. Prostate cancer lesions must be asymptomatic or mildly symptomatic.
All patients will receive abiraterone acetate along with either radium-223 or placebo.
To learn more about the ERA 223 trial and to find out if you may be eligible, please visit: http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php (Trial Number: 15396) or www.clinicaltrials.gov (Study Identifier: NCT02043678)
Augmenix is seeking men to participate in a US clinical trial testing the safety and effectiveness of SpaceOAR System, an investigational medical device. The purpose of this study is to evaluate the safety and effectiveness of an investigational device, the SpaceOAR System, in radiation therapy to treat prostate cancer. It is being studied to see if it can successfully move the rectum away from the prostate. By separating the rectum from the prostate the SpaceOAR gel may eliminate or reduce damage to the rectum from radiation therapy.
To learn more about this study, please visit Augmenix
Additional open trials can be found by going to:
Tomasz M. Beer, MD
Larry Axmaker, Ed.D.
Written from both a patient and clinician perspective by Larry Axmaker, Ed.D., and Tomasz M. Beer, MD, a PCF-funded researcher, this book is an insightful resource for anyone considering clinical trials in addition to standard cancer therapy. Order Here »